Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIFE: Hydroxychloroquine and Prednisone in Recurrent Pregnancy Loss with UCTD
NCT03671174Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine and prednisone in recurrent pregnancy loss (RPL) (3 arms), sponsored by Renji Hospital. Primary endpoint: Live birth rate. Status: unknown.
02
Drugs
hydroxychloroquineprednisone
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT03671174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671174.